Healio
Healio
March 28, 2017
1 min read
Save

Aflibercept for AMD largely maintains visual gains through 212 weeks

Vision gains achieved in the VIEW 1 trial were “largely maintained” at the conclusion of the VIEW 1 Extension Study, according to the study results.

In the four arms of the VIEW 1 trial, 1,217 patients with neovascular age-related macular degeneration were randomized to receive 0.5 mg intravitreal Eylea (aflibercept, Regeneron) injections every 4 weeks, 2 mg of aflibercept every 4 weeks, 2 mg of aflibercept every 8 weeks after three initial monthly doses, or 0.5 mg Lucentis (ranibizumab, Genentech) every 4 weeks. Mean best corrected visual acuity at baseline was 55.6 letters, and at the 96-week conclusion of the VIEW 1 trial, patients gained a mean of 10.2 letters.

In the subsequent prospective, open-label, multicenter extension trial, 323 patients received 2 mg aflibercept on a modified quarterly schedule and then at least every 8 weeks through 212 weeks from the start of VIEW 1. Mean best corrected visual acuity of patients at baseline starting the extension study was 65.3 letters. By 212 weeks, patients in the extension study gained a mean of 7.1 letters from the VIEW 1 baseline.

“From the VIEW 1 baseline, 29.8% of patients gained 15 letters and 8.4% of patients lost 15 letters at week 212. The corresponding proportions of patients who gained or lost 15 letters from the extension study baseline was 3.4% and 8.2%, respectively,” the study authors wrote.

In the extension study, 32.5% of patients experienced a serious non-ocular adverse event and 3.7% of patients experienced a serious ocular adverse event in the study eye. These adverse events were consistent with the safety profile for patients receiving aflibercept for neovascular AMD. – by Robert Linnehan

Disclosure: Kaiser reports he is a consultant for Alcon, Allergan, Bayer HealthCare, Kanghong, Ohr Pharmaceutical, Ophthotech, Novartis and Regeneron Pharmaceuticals. Please see the study for all other authors’ relevant financial disclosures.

Sources/Disclosures

Collapse
Source:

Kaiser PK, et al. Ophthalmology Retina. 2017;doi:10.1016/j.oret.2017.01.004.